Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/appi.ajp.162.5.1021-a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Laboratory of Neuroscience (LIM27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil.
Background: Nearly all individuals with Alzheimer's disease (AD) develop neuropsychiatric symptoms (NPS). Lithium is a mood-stabilizer and is efficient in reducing disruptive behaviors in bipolar-disorder; this characteristic could be an opportunity to investigate the use of lithium in treating behavioral changes in AD.
Method: We tested lithium carbonate treatment in 3xTg-AD and age-matched Wild-type male mice (CEUA/PROCESS: 1605/2020; 4127240122).
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
G. H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Background: Neuropsychiatric Symptoms (NPS) (e.g., aggression, psychosis, anxiety, apathy, depression, agitation, sleep disturbances, repetitive behaviors) occur in 85% of AD patients, and are associated with accelerated decline, out-of-home placement, increased costs, and greatly increased suffering of patients and families.
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
University of Pittsburgh, Pittsburgh, PA, USA.
Background: Recent studies have shown that patients with attention-deficit/hyperactivity disorder (ADHD) are more likely to be diagnosed with mild cognitive impairment (MCI) and Alzheimer's Disease (AD). Increased genetic risk for ADHD, measured with ADHD polygenic risk scores (ADHD-PRS), was associated with a more severe AD presentation, including worse cognitive function and higher tau pathology. Neuropsychiatric symptoms (NPSs) are common in AD and are hypothesized to occur with disease progression.
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.
Background: First-degree relatives of patients suffering from Alzheimer's Dementia (AD) are at increased risk for developing dementia, yet the associations between family history of AD and cognitive dysfunction remain unclear. Our study aims to understand the intricate interplay between familial risk factors and neurocognitive functioning in AD FDRs versus FDRs of other major psychiatric illnesses by comparing the neuro- cognitive functions of unaffected first-degree relatives (FDR) of patients with AD with unaffected FDR of other major psychiatric illness including Schizophrenia(SCHIZ), Substance use disorders(SUD), Obsessive compulsive disorders(OCD) and Bipolar disorder(BPAD). Subsequently, we also compare the Neuro cognitive performance of FDR's of AD at baseline and after two years longitudinally.
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
University of Exeter, Exeter, United Kingdom.
Background: When assessed in the Mild Behavioral Impairment (MBI) framework, late-life onset psychotic like symptoms (MBI-psychosis) are associated with incident cognitive decline and dementia. One approach to examining the genetic basis of this association, is to use Polygenic Risk Scores (PRS) to determine whether genetic propensity for late-life onset psychosis is shared with other traits. We aimed to elucidate the shared genetic liability between Educational Attainment, Intelligence, Reasoning, Memory, Neuroticism, Alzheimer's Disease, Major Depression, Schizophrenia and Bipolar Disorder and Mild Behavioral Impairment (MBI)-Psychosis in later life.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!